The Endo Fails Continue - Uther NAD+ batches retested

5byfive

Explorer
Joined
Mar 29, 2026
Messages
358
Reaction score
0
Location
Birmingham/Al
Cross-posted from The Flying Purple Per Guild:

The Crispy Testing Group spent 2 months collecting vials from 12 different batches of Uther's NAD+, drawn from a span of 6 months, and shipped them off to Janoshik for endotoxin testing. Two things set this off. First, the NA500-0113 batch came back at 984 EU/vial, and as you know that is a fairly high figure: delivered at a high enough dosage of NAD+, or alongside other peptides carrying moderate endotoxin levels, or into a lighter person, it could do harm.

The test set out to establish two things:

A)
whether other batches from the 0113 timeframe carried endo in the same range.

B) whether a trend over time could be extracted, given Uther's own disclosure that fresh raws arrived in Q4 and went into every batch of his NAD+.

The graph, and the COAs that come with it, are below. December plainly marks a change, so pinning this on the new raws looks a safe assumption to make - though firm conclusions deserve caution, because all this data gives is the what, never the why...

Any comments or further detail Uther chooses to offer on these results, on these batches or their products, on batches absent from this round, and on the NAD+ lots still to be released, would be welcome.

One thing you may have spotted: 12 vials went off for testing, but one of them was damaged in shipping, so this round covers 11.

Speaking for our community: hearty thanks to the contributors and donors behind this the Crispy Testing Group, group test !

Finally, these results CAN be shared. At the outset we agreed they would all be open for anyone to use/share, letting those who bought this NAD decide for themselves what to do with the batches they hold.

12.7 EU/vial - NA500-0912

https://verify.janoshik.com/tests/148664-NAD_XXBA5GKTIQPE

11.3 EU/vial - NA500-1101


Janoshik Analytical




11.5 EU/vial - NA500-1109


Janoshik Analytical




602 EU/vial - NA500-1210

https://verify.janoshik.com/tests/150380-NAD_500mg_VBF3VKRVZYRT

657 EU/vial - NA500-1216

https://verify.janoshik.com/tests/134363-Nad_Q5GHP2UHJZWQ

1102 EU/vial (estimated) - NA500-1224

https://verify.janoshik.com/tests/134364-NAD_68YCHQ5RTM3C

1003 EU/vial (estimated) - NA500-0113

h ttps://verify.janoshik.com/tests/134365-NAD_XYXAZ9CUCQF3

1251 EU/Vail (estimated) - NA500-0115

h ttps://verify.janoshik.com/tests/134366-NAD_5D5WS5P7RKPY

889.3 EU/vial - NA500-0122

h ttps://verify.janoshik.com/tests/134367-NAD_G4UGTPIRJYNS

564.5 EU/vial - NA500-0209

h ttps://verify.janoshik.com/tests/134368-NAD_7BV3BRMY2MKP

737.5 EU/vial - NA500-0306

h ttps://verify.janoshik.com/tests/134369-NAD_GV1B2SA61TNJ

Damaged / not tested - NA500-1207

NOTE: Results >1000EU are estimated, not actual results.
 
The month-by-month batch graph makes it obvious where the problems started, and there are some good results in there too.
 
Wasn't it February when he mentioned moving to pricier raw materials to cut down on endos? That's what I remembered. This isn't reassuring.
 
Back
Top